Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis

Krystal Bergin, Flora Yuen, Craig Wallington-Beddoe, Anna Kalff, Shreerang Sirdesai, John Reynolds, Andrew Spencer

Research output: Contribution to journal › Meeting Abstract › peer-review

Fingerprint

Dive into the research topics of 'Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science